PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. (Q53793413)

19 May 2018

title

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. (English)

1 reference

19 May 2018

1 reference

Brad H Nelson

4

0 references

Katy Milne

series ordinal

2

object named as

Katy Milne

1 reference

19 May 2018

David Li-Kroeger

series ordinal

3

object named as

David R Kroeger

1 reference

19 May 2018

author name string

John R Webb

series ordinal

1

1 reference

19 May 2018

language of work or name

English

0 references

publication date

16 March 2016

1 reference

19 May 2018

published in

Gynecologic Oncology

1 reference

19 May 2018

volume

141

1 reference

19 May 2018

issue

2

1 reference

19 May 2018

page(s)

293-302

1 reference

19 May 2018

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

PD-1 signaling in primary T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

7 January 2021

PD-1/PD-L1 inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Neoantigens in cancer immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Classifying Cancers Based on T-cell Infiltration and PD-L1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

PD-L1 expression on tolerogenic APCs is controlled by STAT-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Overcoming T cell exhaustion in infection and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

CD25 Identifies a Subset of CD4+FoxP3- TIL That Are Exhausted Yet Prognostically Favorable in Human Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

New insights into tumor immunity revealed by the unique genetic and genomic aspects of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Overall survival and PD-L1 expression in metastasized malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

PD-1 blockade induces responses by inhibiting adaptive immune resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.03.008

10.1016/J.YGYNO.2016.03.008

7 January 2021

Identifiers

DOI

1 reference

19 May 2018

1 reference

19 May 2018